Saquinavir (Roche protease inhibitor) at higher doses.

Abstract excerpt

The protease inhibitor developed by Hoffmann-LaRoche, saquinavir, is currently in large-scale clinical trials at a dose of 1,800 mg per day. In an attempt to increase the bioavailable levels of the drug, another study is being conducted comparing doses of 3,600 and 7,200 mgs per day. Both doses significantly decreased viral load and increased CD4 counts, with the higher dose leading to greater and longer lasting...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CD4 Lymphocyte Count
• Share to HIV Protease
• Share to HIV Protease Inhibitors